All In Biotech

Drug Trial Radar · NCT06379685

Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.

Phase I Clinical Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers.

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Dec 30, 2025

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I clinical study to evaluate the safety and tolerability of PRO-190 ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface integrity, changes in the ocular comfort index (OCI) score, and IOP measurement compared to Systane Ultra®.

Conditions

  • Dry Eye
  • Dry Eyes Chronic
  • Dry Eye Syndromes

Interventions

  • PRO-190Drug

    Propylene glycol 0.3% - Polyethylene glycol 400 0.3%. Ophthalmic solution.

  • Systane Ultra®Drug

    Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Unexpected Related Adverse ReactionsTime frame: Through study completion, an average of 12 days. Evaluations will take place on days 0 (Basal Visit), 8 (Final Visit) and 12 (Safety Call) after the inclusion of each subject.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.